In this video, Robert H. Vonderheide, MD, DPhil, explains how the unique pathology of breast cancer poses a challenge to immunotherapy and offers optimistic reports from recent trials of the PD-1 inhibitors in women with advanced triple-negative disease. Also includes a discussion of RADVAX (radiation vaccine) therapy, adaptations of CAR-T therapy (cMET T cells) and TERT vaccine therapy, all in ongoing clinical trials at the Abramson Cancer Center.
Related Links:
Published
February 13, 2018
Created by
BROADCASTMED